Brazilian Peppertree (Schinus terebinthifolia Raddi)
1. Identity and Botanical Description
Taxonomy and Nomenclature
Schinus terebinthifolia is a species of flowering plant in the cashew family, Anacardiaceae, that is native to subtropical and tropical South America. Common names include Brazilian peppertree, aroeira, rose pepper, broadleaved pepper tree, wilelaiki (or wililaiki), Christmasberry tree, and Florida holly. The correct spelling of the species epithet, as formally resolved, is terebinthifolia (feminine), though the misspelling terebinthifolius (masculine) pervades the older literature. The misspelling is due to considerable historic confusion as to the correct gender of the genus name; as of 2015, this has been resolved with the determination that the correct gender of Schinus is feminine, and adjectival names within the genus must be spelled accordingly.
Schinus terebinthifolia Raddi and Schinus molle L. are two of approximately 30 Schinus species described in the literature and belong to the Anacardiaceae family. Whereas S. terebinthifolia (Brazilian peppertree) is indigenous to Brazil, S. molle (Peruvian peppertree) initially comes from the Andean region, mainly Peru. The formal scientific description was provided by the Italian botanist Giuseppe Raddi in 1820. European explorers and naturalists first documented the species during expeditions in the 18th and early 19th centuries, with Italian botanist Giuseppe Raddi providing its formal scientific description in 1820 based on specimens from Brazil.
The plant occupies a confirmed phylogenetic classification: Schinus terebinthifolia is classified in the kingdom Plantae, phylum Tracheophyta, class Magnoliopsida, order Sapindales, family Anacardiaceae, genus Schinus.
Morphology
Brazilian peppertree is a sprawling shrub or small tree, with a shallow root system, reaching a height of 7–10 m (23–33 ft). The branches can be upright, reclining, or nearly vine-like, all on the same plant. Its plastic morphology allows it to thrive in all kinds of ecosystems, from dunes to swamps, where it grows as a semiaquatic plant. It is primarily noted for glossy, evergreen, odd-pinnate leaves which have a pepper-like aroma when bruised, white late summer flowers in panicles, and showy bright red berries which ripen in winter.
Distribution
The species is native to Argentina, Brazil, and Paraguay. In the United States, it arrived in Florida in the 1840s, followed by Hawaii before 1911; similar introductions occurred in Australia during the early 1910s and in South Africa around 1919, often through botanical gardens and private estates. Brazilian pepper tree was introduced into the U.S. in the 1800s as an ornamental shrub/tree. Over time, it has proved to be an aggressive and invasive spreader that displaces native vegetation.
Common Preparations and Dosage Forms
Virtually all parts of this tropical tree have been used for medicinal purposes throughout the tropics including its leaves, bark, fruit, seeds, resin, and oleoresin or balsam. Preparations encountered in both traditional and research contexts include:
- Bark decoctions and tinctures: The importance of the plant has prompted its inclusion in the Brazilian Pharmacopoeia, in which the decoction of its bark is used as an anti-inflammatory agent.
- Essential oils: Obtained by hydrodistillation from leaves, fruits, and twigs and studied extensively for antimicrobial, anti-inflammatory, and analgesic properties.
- Hydroalcoholic and ethanolic leaf extracts: Used in experimental and clinical research, including mouthwash formulations and topical preparations.
- Vaginal gel: Recommended treatments for bacterial vaginosis include vaginal formulations of metronidazole gel, clindamycin cream, and Schinus terebinthifolia Raddi gel.
- Dried fruit (pink peppercorns): Although it is not a true pepper (Piper), its dried drupes are often sold as pink peppercorns. The seeds can be used as a spice, adding a pepper-like taste to food.
2. Traditional and Historical Use
Indigenous and Folk Traditions in South America
Brazilian peppertree is native to subtropical and tropical regions of South America, including Brazil, Argentina, Paraguay, and Uruguay, where indigenous communities have utilized the plant for centuries in traditional medicine to treat wounds, infections, and inflammatory conditions due to its antiseptic and anti-inflammatory properties.
Peppertree is included in the Brazilian Pharmacopoeia and has served as a staple in Brazilian traditional medicine. Almost all parts of the plant, including leaves, bark, fruit, seeds, and resin, have been used to treat a variety of ailments. In particular, it has been used traditionally for its antiseptic and anti-inflammatory qualities in the treatment of wounds and ulcers, bruises, hemoptysis, diarrhoea, chills, tumours, and arthritis, as well as urinary and respiratory infections.
In folk medicine, Schinus terebinthifolia Raddi (Anacardiaceae) has been used as a remedy for ulcers, respiratory problems, wounds, rheumatism, gout, diarrhea, skin ailments, and arthritis, as well as to treat tumors and leprosy.
The plant's leaves have been commonly used worldwide in the management of venereal diseases, womb inflammation, urinary tract infections, skin wounds, diarrhea, and gastroduodenal ulcer.
In Brazilian folk medicine, Schinus terebinthifolia Raddi is used due to the wound-healing and antiseptic properties of its bark, and its fruits are used as a condiment.
Traditional Use of Bark
Schinus terebinthifolia Raddi (Anacardiaceae), popularly known as red aroeira, is used in traditional medicine to treat inflammatory, gastric, and respiratory disorders. The bark decoction in particular became sufficiently well-established in Brazilian ethnomedicine that it was ultimately codified in the Brazilian Pharmacopoeia as a recognized anti-inflammatory preparation.
Traditional Use of Fruit and Berries
The small pink fruits from this tree have been used by traditional Amazonian healers for generations to treat infections and wounds. The Brazilian peppertree has a variety of uses in traditional medicine, including several dermatological indications. Specifically, the fruit and leaves are used in balms for wounds and ulcers.
3. Key Constituents and Active Compounds
General Phytochemical Profile
Phytochemical characterization of Brazilian peppertree reveals that the plant contains tannins, alkaloids, flavonoids, steroidal saponins, sterols, terpenes, triterpenoids, and a large amount of essential oil comprised of fatty acids and other natural chemicals. The essential oil present in the leaves, bark, and fruit is a rich source of chemicals (over 50 constituents identified thus far) including biologically active triterpenes and sesquiterpenes.
The species has been frequently studied from a chemical viewpoint, and the presence of several constituents has been established, including phenols, pentagalloylglucose (i.e., a precursor of many complex structures of tannins), and flavonoids. Chemical analysis of the bark of S. terebinthifolia has revealed the presence of anthraquinones, flavonoids, xanthones, saponins, pentacyclic triterpenes, and free steroids.
Polyphenolic Compounds
The phytochemical profile of ethyl acetate leaf extracts is rich in polyphenolic compounds, mostly derived from gallic and ellagic acids. Myricetin-O-pentoside and quercetin-O-rhamnoside are the major peaks of chromatographic analysis. HPLC analysis revealed that gallic acid, methyl gallate, and 1,2,3,4,6-pentagalloylglucose are the major aromatic components of the ethyl acetate fraction of S. terebinthifolia.
Phenol and flavonoid contents were measured at 19.2 ± 0.4 and 93.8 ± 5.2 of gallic acid or quercetin equivalents/g, respectively. LC–MS analysis identified 43 compounds, of which myricetin-O-pentoside and quercetin-O-rhamnoside were the major peaks.
Essential Oil Composition
The essential oil composition varies considerably depending on the plant part (leaves, fruit, or twigs) and geographic origin. Monoterpenes and sesquiterpenes constitute the predominant chemical classes. GC/MS analysis of the leaf essential oil identified 28 constituents, including alpha-pinene (24.3%), gamma-muurolene (16.6%), and myrcene (13.7%) as major compounds. Sesquiterpenes (47.8%), monoterpenes (34.4%), oxygenated sesquiterpenes (11.8%), and oxygenated monoterpenes (1.1%) are predominant in the essential oil constitution.
From fruit essential oil, a different monoterpene-dominant profile is observed. The essential oil of S. terebinthifolia fruit showed predominance of monoterpenes (85.81%), presenting as major constituents δ-3-carene (30.37%), limonene (17.44%), α-phellandrene (12.60%), α-pinene (12.59%), myrcene (5.82%), and o-cymene (3.46%); sesquiterpenes appeared as a minor proportion (5.34%).
In essential oils prepared from leaves in another study, forty-nine constituents were identified (97.9% of the total), with germacrene D (23.7%), bicyclogermacrene (15.0%), β-pinene (9.1%), and β-longipinene (8.1%) as the main compounds.
The most important phytochemicals of Schinus terebinthifolia fruit oil are β-pinene, α-pinene, δ-3-carene, α-phellandrene, limonene, p-cymene, β-phellandrene, monoterpene and sesquiterpene hydrocarbons. The variability across studies is notable and likely reflects differences in geography, season, plant sex, and extraction method. Research suggests that the sex of the plant clearly determines the chemical composition of both volatile and non-volatile compounds.
Pentagalloylglucose (PGG)
One of the most pharmacologically studied non-volatile constituents is pentagalloylglucose (PGG), a bioactive gallotannin. A crude extract of Schinus terebinthifolia leaves exhibited 80% inhibition against Acinetobacter baumannii at 256 µg/mL and underwent bioassay-guided fractionation, leading to the isolation of pentagalloyl glucose (PGG). PGG has been well studied for antimicrobial activity in gram-positive bacteria, exhibiting growth and biofilm inhibition via iron chelation.
Triterpenoid Acids
Three bioactive triterpenoid acids have been isolated from S. terebinthifolia fruit: 3-oxo-olean-12-en-28-oic acid, 3-oxotirucalla-7,24Z-dien-26-oic acid, and 3α-hydroxytirucalla-7,24 Z-dien-27-oic acid. These compounds are of particular interest for their anti-virulence activity against Staphylococcus aureus, discussed further below.
4. Mechanisms of Action
Anti-Inflammatory Mechanisms
Oral pre-treatment with the ethyl acetate fraction of S. terebinthifolia (100 mg/kg) significantly inhibited paw edema induced by compound 48/80 and the allergic paw edema. The fraction (100 and 200 mg/kg) also inhibited the edema induced by histamine (100 µg/paw), preventing mast cell degranulation and, consequently, histamine release in Wistar rat peritoneal mast cells.
At the cellular level, bark extract of S. terebinthifolia (250, 500, and 1,000 µg/mL) reduced histamine-induced contractions by 9.1 ± 1.8, 50.2 ± 2.0, and 68.9 ± 2.0%, respectively, in isolated guinea pig ileum, without inhibiting contractions induced by carbachol or KCl. The association of the extract with hydroxyzine increased the inhibitory effect substantially. The extract (100, 200, and 400 mg/kg) decreased paw edema from its peak by 33.9, 48.4, and 54.8%, respectively. Altogether, results suggest that the bark extract has an antihistaminic effect (H₁).
Antibacterial Mechanisms
The antibacterial activity of the essential oil is associated with its terpenoid content. The pharmacological action demonstrated by the essential oil may be mediated by constituents such as alpha-pinene, since previous studies have shown that this compound acts as a potentiator of the action of antibiotics. For the gallotannin PGG, PGG exhibits growth and biofilm inhibition via iron chelation against gram-positive bacteria, while its mechanism against gram-negative organisms like A. baumannii involves additional pathways.
Anti-Virulence Mechanism via Quorum Sensing Inhibition
Staphylococcus aureus relies on quorum sensing to exert virulence to establish and maintain infection. Prior research demonstrated the potent quorum sensing inhibition effects of "430D-F5," a refined extract derived from the fruits of Schinus terebinthifolia, a medicinal plant used for the traditional treatment of skin and soft tissue infections. Each isolated triterpenoid acid compound inhibits all S. aureus accessory gene regulator (agr) alleles (IC₅₀ 2–70 μM). Dose-dependent responses were also observed in agr-regulated reporters for leucocidin A (lukA, IC₅₀ 0.4–25 μM) and glycerol ester hydrolase or lipase (gehB, IC₅₀ 1.5–25 μM).
Antifungal Mechanism
S. terebinthifolia was found to have MIC and MFC values of 625 µg/mL on Candida tropicalis, whereas nystatin showed MIC and MFC of 6.25 µg/mL. Results suggest that S. terebinthifolia tincture acts on fungal cell walls, since the sorbitol test indicated a MIC of 1,250 µg/mL. It may be concluded that S. terebinthifolia has potential in vitro antifungal activity against C. tropicalis strains, and probably acts by inhibiting fungal cell wall formation.
Analgesic Mechanism
The analgesic properties of Schinus terebinthifolia essential oil (STEO) have been experimentally validated, supporting its traditional use for pain relief. STEO induces acute antinociceptive effects in adult zebrafish and reduces hyperalgesia in neuropathic rat models. These effects are primarily attributed to its terpenoid constituents, notably R-(+)-limonene and α-phellandrene.
Antioxidant Mechanism
Incubation with the ethyl acetate leaf extract decreased the amount of DPPH radical (EC₅₀ of 54.5 ± 2.4 µg/mL) and lipoperoxidation at 200–500 µg/mL. The antioxidant activity is primarily attributed to the high polyphenol content, particularly gallic acid, ellagic acid derivatives, and flavonoid glycosides.
5. Scientific Evidence by Health Area
5.1 Antimicrobial Activity
Antibacterial — In Vitro and Preclinical Evidence
Previous studies have shown that the species has anti-inflammatory, antimicrobial, anti-rheumatic, and healing activities. A substantial body of laboratory research has investigated its effects on clinically relevant bacteria. A large body of research demonstrates the significant antimicrobial activities of Schinus terebinthifolia Raddi, including antibiotic-enhancing effects against standard and multidrug-resistant strains of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.
Against multidrug-resistant gram-negative pathogens, PGG inhibited growth of both carbapenem-resistant and susceptible A. baumannii (MIC 64–256 µg/mL), and also exhibited activity against Pseudomonas aeruginosa (MIC 16 µg/mL) and Staphylococcus aureus (MIC 64 µg/mL). Previous pharmacological studies of PGG have found low oral bioavailability but potential for intravenous administration, with possibilities for nanoparticle-based and microbubble-based delivery. PGG's activity against carbapenem-resistant A. baumannii, an urgent healthcare threat, supports its further investigation for anti-infective therapy.
Evidence strength: All antibacterial evidence reviewed is preclinical (in vitro and animal models). No controlled human trials of oral or systemic antibacterial applications have been published.
Anti-MRSA Quorum Sensing Inhibition — Preclinical
Researchers at Emory University conducted a systematic bioassay-guided investigation of S. terebinthifolia fruit extract. Investigation of botanical folk medicines for wounds and infections led the research team to study Schinus terebinthifolia as a potential source of virulence inhibitors, reporting the inhibitory activity of a flavone-rich extract "430D-F5" against S. aureus. Subsequently, three bioactive triterpenoid acids were isolated from 430D-F5 and found to inhibit agr-dependent virulence pathways. This represents the first time that the anti-quorum sensing activity of tirucallane-type triterpenoids was described.
Evidence strength: Compelling mechanistic preclinical data. No human clinical trials have yet evaluated this anti-MRSA application.
Antifungal Activity — In Vitro Evidence
Schinus terebinthifolia has proven efficacy against bacteria and fungi of clinical interest. Against the fungal pathogen Sporothrix brasiliensis, the crude extract of S. terebinthifolia inhibited the growth of S. brasiliensis (MIC: 0.5–1.0 µg/mL), while partitioned extracts (dichloromethane, ethyl acetate, and butanol) demonstrated growth inhibition at 8 µg/mL through a fungistatic mechanism. Due to its in vitro efficacy against S. brasiliensis and its known pharmacological safety, S. terebinthifolia is a candidate to be tested using in vivo models of sporotrichosis.
Evidence strength: Preliminary in vitro only. No clinical trial data exist for antifungal applications.
5.2 Oral Health (Gingivitis)
One randomized controlled clinical trial has been conducted in humans. A controlled trial investigated the clinical efficacy of an experimental mouthwash containing S. terebinthifolia in reducing biofilm-induced gingivitis levels in children aged 9–13 years. This was a randomized, controlled, triple-blind, phase II clinical trial with children (n = 27) presenting with biofilm-induced gingivitis. The sample was randomized into an experimental group (0.3125% ST, n = 14) and a control group (0.12% chlorhexidine/CHX, n = 13). Products were masked as regards color, flavor, and aroma. The intervention protocol consisted of supervised rinsing of 10 mL/day for 1 minute for 10 days.
The mouthwash containing Schinus terebinthifolia presented significant anti-inflammatory activity after a 10-day use regimen by children having moderate biofilm-induced gingivitis, but it was not able to mitigate biofilm accumulation. The authors noted the trial indicates encouraging perspectives on the development of a product containing S. terebinthifolia stem bark tincture to be adjunctive in the treatment of biofilm-induced gingivitis, but further investigation should consider a more detailed pharmacotechnical analysis and the noted shortcomings.
Schinus terebinthifolia is characterized as an herbal agent with antimicrobial, anti-inflammatory, antiulcerogenic, bactericidal, and bacteriostatic activity on some bacterial species present in periodontal disease.
Evidence strength: One small (n = 27) randomized triple-blind phase II clinical trial. Results are preliminary; the study was not powered for definitive conclusions, and larger confirmatory trials are needed.
5.3 Bacterial Vaginosis
A clinically important randomized controlled trial compared a Schinus terebinthifolia vaginal preparation to standard therapy. A 7.4% vaginal extract of the Brazilian pepper tree was compared with 0.75% vaginal metronidazole for the treatment of bacterial vaginosis, used at bedtime for 7 nights. The condition was diagnosed using the combined criteria of Amsel and Nugent in two groups of 140 and 137 women, aged between 18 and 40 years.
According to Amsel's criteria separately, 29 patients (21.2%) treated with the extract and 87 (62.1%) treated with metronidazole were considered to be cured (P < 0.001). The Schinus extract was thus significantly inferior to metronidazole in achieving cure by microbiological criteria.
A secondary consideration favoring the Schinus formulation is its apparent selectivity: in vitro, Lactobacillus gasseri was resistant to S. terebinthifolia Raddi vaginal gel, as no inhibition zones were observed. In contrast, L. gasseri showed moderate susceptibility to metronidazole vaginal gel and high sensitivity to clindamycin vaginal cream. Since lactobacilli, particularly L. gasseri, comprise over 95% of the vaginal microbiota, maintaining this population is critical for vaginal health. The inhibitory effects of clindamycin and metronidazole on L. gasseri suggest these treatments may disrupt the vaginal microbiome, potentially leading to recurrent BV.
Evidence strength: One adequately powered randomized controlled trial (n = 277). The Schinus vaginal gel was statistically inferior to metronidazole for microbiological cure, though its microbiome-sparing profile suggests potential utility as an adjunct or in recurrence prevention. Further trials are needed to clarify these roles.
5.4 Anti-Inflammatory and Antioxidant Effects
Research has evaluated the anti-inflammatory and antioxidant effects of ethyl acetate extract from the leaves of Schinus terebinthifolia. Total phenols and flavonoids, chemical constituents, in vitro antioxidant activity (DPPH and lipoperoxidation assays), and cytotoxicity in L929 fibroblasts were determined. In vivo anti-inflammatory and antioxidant properties were evaluated using the TPA-induced ear inflammation model in mice.
Animal model experiments have shown dose-dependent effects: the bark extract (100, 200, and 400 mg/kg) decreased histamine-induced paw edema from its peak by 33.9, 48.4, and 54.8%, respectively, comparable to hydroxyzine (70 mg/kg) at 56.5%.
Evidence strength: Well-replicated across multiple animal models and in vitro systems. No clinical trials specifically assessing systemic anti-inflammatory outcomes in humans have been published.
5.5 Analgesic and Neuropathic Pain
The analgesic properties of Schinus terebinthifolia essential oil have been experimentally validated, supporting its traditional use for pain relief. The essential oil induces acute antinociceptive effects in adult zebrafish and reduces hyperalgesia in neuropathic rat models. Leaf extracts have clinically demonstrated pain-relieving activity in mice and antispasmodic properties in rats and guinea pigs.
Evidence strength: Preclinical (animal models) only. No human clinical trials on analgesic applications have been published.
5.6 Antiparasitic / Antileishmanial Activity
Phytomedicine, particularly essential oils, is a promising alternative in the treatment of leishmaniasis. The chemical composition and antileishmanial properties of essential oil from leaves of Schinus terebinthifolia were determined. Antileishmanial activity on promastigotes of Leishmania amazonensis was assayed, followed by evaluation of effects on the mitochondrial membrane potential and redox state of the parasite.
Evidence strength: In vitro/preclinical only.
5.7 Insecticidal and Larvicidal Activity
GC-MS analysis of fruit essential oil revealed major constituents including δ-3-carene (55.43%), α-pinene (16.25%), and sylvestrene (10.67%), together representing 86.51% of the essential oil. The larval median lethal dose (LD₅₀) of the essential oil against Stegomyia aegypti (dengue vector) was between 172.44–344.88 µg/mL. Bilobol, an alkylresorcinol isolated from Schinus terebinthifolia, demonstrated larvicidal activity against Aedes aegypti (LC₅₀ 7.67 mg/L in less than 24 h).
Evidence strength: Preliminary laboratory data. No field efficacy trials in humans have been conducted.
6. Body Systems and Health Areas
- Integumentary/Dermatology: Traditional use for wound healing, ulcers, and skin infections; supported by antimicrobial and anti-MRSA preclinical studies.
- Immune and Inflammatory System: Anti-inflammatory activity demonstrated in multiple animal models; antihistaminic activity in guinea pig and rat models; anti-allergic effects involving mast cell stabilization documented in rodent studies.
- Oral Health: One human RCT supports reduction of gingivitis-related gingival inflammation with a bark tincture mouthwash.
- Reproductive/Genital Tract: A large RCT evaluated a vaginal gel for bacterial vaginosis; the gel spares beneficial Lactobacillus flora in vitro, though it was inferior to metronidazole for microbiological cure.
- Musculoskeletal: Traditional use for arthritis, rheumatism, and gout; preclinical anti-inflammatory data support this use; xanthine oxidase inhibitory activity has been reported in bark extracts, relevant to gout.
- Respiratory System: Traditional use for respiratory infections and as an antispasmodic; antihistaminic mechanism in animal models is consistent with this use.
- Gastrointestinal: Traditional use for diarrhea, gastroduodenal ulcers, and gastric disorders; antiulcerogenic activity reported in preclinical studies.
- Nervous System/Pain: Antinociceptive and anti-neuropathic pain effects in animal models; analgesic essential oil constituents identified.
- Antioxidant/Metabolic: Significant in vitro antioxidant capacity attributed to high polyphenol content including gallic acid, myricetin, and quercetin derivatives.
7. Dosage Forms and Reported Dosages
The following dosages are reported exclusively as stated in published research sources; they do not represent clinical recommendations.
- Bark extract, oral (animal toxicity study): The subacute toxicity study used oral doses in Wistar rats of both sexes: for the acute toxicity test, the dried extract was administered at doses from 0.625 to 5.0 g/kg; in the subacute toxicity test, doses of 0.25, 0.625, and 1.5625 g/kg/day were used for 45 consecutive days.
- Ethyl acetate fraction, oral (animal anti-allergic study): Oral pre-treatment with the ST fraction at 100 mg/kg significantly inhibited histamine-induced edema; the fraction at 100 and 200 mg/kg also inhibited histamine-induced edema via mast cell stabilization.
- Bark extract, in vitro antihistaminic: Bark extract at concentrations of 250, 500, and 1,000 µg/mL reduced histamine-induced contractions by 9.1 ± 1.8, 50.2 ± 2.0, and 68.9 ± 2.0%, respectively.
- Bark extract, in vivo (rat paw edema): Bark extract at 100, 200, and 400 mg/kg decreased histamine-induced paw edema from its peak by 33.9, 48.4, and 54.8%, respectively.
- Mouthwash (human clinical trial): In a randomized triple-blind trial in children aged 9–13 years (n = 27), the experimental group used a 0.3125% S. terebinthifolia mouthwash; the protocol consisted of supervised rinsing of 10 mL/day for 1 minute for 10 days.
- Vaginal gel (human clinical trial): A 7.4% vaginal extract of Schinus terebinthifolia was used at bedtime for 7 nights, compared with 0.75% vaginal metronidazole gel.
- Triterpenoid acids, in vitro anti-MRSA: Each isolated triterpenoid acid inhibits all S. aureus agr alleles (IC₅₀ 2–70 μM); dose-dependent responses were also observed for leucocidin A (lukA, IC₅₀ 0.4–25 μM) and glycerol ester hydrolase (gehB, IC₅₀ 1.5–25 μM).
8. Safety Considerations and Toxicology
Preclinical Toxicology
The acute and subacute administration of the dried extract of Schinus terebinthifolia bark did not produce toxic effects in Wistar rats. The species has long been used in traditional Brazilian medicine, especially to treat inflammatory and haemostatic diseases, and the objective of the study was to evaluate the acute and subacute toxicity (45 days) via the oral route in rats of both sexes. In the acute toxicity test, Schinus terebinthifolia did not produce any toxic signs or deaths. The subacute treatment with Schinus terebinthifolia did not alter either the body weight gain or the food and water consumption.
However, one source notes that bark aqueous extract had toxic potential in rats if administered chronically. This suggests that the form of extract and duration of exposure may affect the toxicological profile.
Anacardiaceae Family Cross-Reactivity
Brazilian peppertree belongs to the same family as poison ivy, poison oak, and poison sumac (Anacardiaceae), and has allergen-causing properties. Individuals with known hypersensitivity to members of the Anacardiaceae family (including cashew, mango, and poison ivy) may be at elevated risk of cross-reactive allergic responses.
Dermal and Sensitization Concerns
The seeds are known to cause rashes, vomiting, and diarrhoea in some sensitive individuals. Airborne exposure to pollen and volatile compounds has been documented to cause respiratory irritation in individuals working near or with the plant.
PGG Bioavailability Limitations
Previous pharmacological studies of PGG have found low oral bioavailability, but potential for intravenous administration with possibilities for nanoparticle-based and microbubble-based delivery. This limits the clinical translatability of in vitro antimicrobial findings from PGG-containing extracts intended for oral use.
Cytotoxicity Window
A mammalian cytotoxicity assay with human keratinocytes (HaCaTs) yielded an IC₅₀ for PGG of 256 µg/mL, which is at the same concentration as the MIC for carbapenem-resistant A. baumannii, indicating a narrow therapeutic window for PGG at the highest bacterial inhibitory concentrations and underscoring the need for formulation optimization.
Regulatory Status
Peppertree is included in the Brazilian Pharmacopoeia as a recognized botanical. The species does not hold approved medicinal product status in the European Union or the United States. In the United States, it is classified as one of the most invasive species in Florida, where a state law prohibiting the sale, cultivation, and transportation of Schinus terebinthifolia was passed by the Florida legislature in 1990, which has implications for its commercial availability in that state.
Species Confusion
Both S. terebinthifolia (Brazilian peppertree) and S. molle (Peruvian peppertree) belong to the Anacardiaceae family and are frequently confused in commerce and literature. Their phytochemical profiles differ meaningfully, and pharmacological findings from one species should not be uncritically extrapolated to the other. Authentication using UHPLC analysis of anthocyanin profiles is recommended to distinguish them.
References
Go back